Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sibeprenlimab rollover extension study in IgA nephropathy
NL-OMON59365Phase 3Active, not recruiting
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sibeprenlimab in IgA nephropathy (IgAN), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Safety and tolerability. Started Oct 2025; status: active, not recruiting.
02
Drugs
sibeprenlimab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NL-OMON59365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59365.